President and CEO Ned McCoy shared with Becker's some of the company's key objectives for the year, including the launch of some of the first medications from its Petersburg, Va.-based plant, the ...

The 13th Alzheimer’s & Parkinson’s Drug Development Summit is the only industry-focused, end-to-end meeting that provides comprehensive coverage from early discovery to late-stage development focused ...

Three Democratic senators want answers from Health and Human Services Secretary Robert F. Kennedy Jr. about his private meetings with drugmakers alongside President Trump at his Mar-a-Lago club in ...

As of fiscal 2024, the firm held roughly $3.1 billion in cash and equivalents with a total debt balance of $9 billion. The firm has done a great job in bringing this balance down over the last three ...

The NDS system facilitates the daily management of licit movements, production, distribution and consumption as well as international trade of controlled (international and national) substances in ...

(The Hill) – Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has made psychiatric medications a focus of his review of the country’s childhood chronic disease crisis, claiming ...

will be co-hosting a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit. The workshop will review methods of screening participants for clinical trials to ...

Cognition Therapeutics (CGTX) announced that Mary Hamby, PhD will be co-hosting a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit. The workshop will review ...

The Hanson Wade Neuroimmunology Drug Development Summit is taking place February 25-27, 2025 in Boston, MA. The workshop, titled "Patient Stratification for Precision Medicine in Neuroscience: How Can ...

Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with its antibody-drug conjugates (ADCs). Under the agreement, Summit will supply ...

Summit Therapeutics (NASDAQ:SMMT) has entered a clinical trial collaboration to evaluate its cancer drug, ivonescimab, in combination with Pfizer (NYSE:PFE) antibody drug conjugates across ...